Adjuvant Therapy in Gall Bladder Cancera
Publisher
Springer Singapore
Reference70 articles.
1. Agrawal S, Mohan L, Mourya C, Neyaz Z, Saxena R. Radiological downstaging with neoadjuvant therapy in unresectable gall bladder cancer cases. Asian Pac J Cancer Prev. 2016;17(4):2137–40. 2. Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, Thomas CR Jr, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015a;33(24):2617–22. https://doi.org/10.1200/JCO.2014.60.2219. Epub 2015 May 11 3. Bergquist JR, Shah HN, Habermann EB, Hernandez MC, Ivanics T, Kendrick ML, Smoot RL, Nagorney DM, Borad MJ, McWilliams RR, Truty MJ. Adjuvant systemic therapy after resection of node positive gallbladder cancer: time for a well-designed trial? (Results of a US-national retrospective cohort study). Int J Surg. 2018;52:171–9. https://doi.org/10.1016/j.ijsu.2018.02.052. Epub 2018 Feb 26 4. Bizama C, Garcia P, Espinoza JA, Weber H, Leal P, Nervi B, et al. Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. Cancer Treat Rev. 2015;41(3):222–34. https://doi.org/10.1016/j.ctrv.2015.01.003. 5. Chaudhari VA, Ostwal V, Patkar S, Sahu A, Toshniwal A, Ramaswamy A, Shetty NS, Shrikhande SV, Goel M. Outcome of neoadjuvant chemotherapy in “locally advanced/borderline resectable” gallbladder cancer: the need to define indications. HPB (Oxford). 2018;20(9):841–7. https://doi.org/10.1016/j.hpb.2018.03.008. Epub 2018 Apr 26
|
|